Zydus Cadila has commercially launched its Mesalamine Delayed Release Tablets USP, 1.2g in the US market. Zydus was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda® and is currently the only generic available to patients in the US. The drug is indicated for the treatment of mild to moderate ulcerative colitis which affects approximately 700,000 people within the US.
The group has received 26 final ANDA approvals from the USFDA and 2 tentative ANDA approvals since January 2017. The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.544.25 as compared to the previous close of Rs. 524.95. The total number of shares traded during the day was 110480 in over 2674 trades.
The stock hit an intraday high of Rs. 549.55 and intraday low of 527.35. The net turnover during the day was Rs. 59462599.
Source: Zydus launches Mesalamine Delayed Release Tablets in the US
No comments:
Post a Comment